Apaziquone

DRUG6 trials

Sponsors

Spectrum Pharmaceuticals, Inc

Conditions

Bladder CancerBladder Neoplasms

Phase 2

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

CompletedNCT00141531

Spectrum Pharmaceuticals, IncBladder Neoplasms

Start: 2005-07-31End: 2009-12-31Updated: 2012-06-14

Phase 3

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)

CompletedNCT00461591

Spectrum Pharmaceuticals, IncBladder Cancer

Start: 2007-04-30End: 2012-01-31Updated: 2021-03-30

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

CompletedNCT00598806

Spectrum Pharmaceuticals, IncBladder Cancer

Start: 2007-08-31End: 2012-01-31Updated: 2017-11-13

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

TerminatedNCT01410565

Spectrum Pharmaceuticals, IncBladder Cancer

Start: 2011-07-31End: 2014-03-31Updated: 2016-12-13

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

TerminatedNCT01469221

Spectrum Pharmaceuticals, IncBladder Cancer

Start: 2012-01-31End: 2013-04-30Updated: 2017-12-15

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

TerminatedNCT02563561

Spectrum Pharmaceuticals, IncBladder Cancer

Start: 2015-10-09End: 2017-03-10Updated: 2021-10-27